Toggle menu

ATTEST2 Trial

Start date:
July 2017
End date:
January 2021
Co-ordinated by:
The Stroke Research Team
Main trial site:
NHS Greater Glasgow & Clyde

ATTEST 2 aims to test tenecteplase in a large clinical trial to establish whether it is a better drug than alteplase for use in thrombolysis. This will involve a large number of hospitals in the UK, and possibly overseas. People who are considered suitable for thrombolysis will be allocated at random to receive either the current standard treatment with alteplase, or tenecteplase, and will be followed up for the first 90 days to measure the effects on recovery.
Even if there are no significant differences between between the two drugs, tenecteplase is less expensive and much easier to give to patients than alteplase, needing a single injection only. Alteplase has to be given as an injection followed by a longer injection over an hour. This advantage of tenecteplase alone would have worthwhile benefits to the patient.

Trial Design
Prospective Randomised Open, Blinded End-point (PROBE) – Phase III

Principal Investigator
Dr. Will Whitely, Stroke Medicine, University of Edinburgh & NHS Lothian

Chief Investigator

Dr William Whitely

Scottish Senior Clinical Fellow and Consultant Neurologist

Local PI

Dr Matt Reed

Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

Research Team

Rachel O'Brien

Lead Research Nurse

Allan MacRaild

Stroke Lead Research Nurse

Polly Black

Senior Research Nurse

Caroline Blackstock

AMU Senior Research Nurse

Alison Williams

Senior Research Nurse

Fiona McCurrach

Senior Research Nurse

Seona Burgess

Senior Stroke Research Nurse

Jessica Teasdale

Senior Research Nurse - Stroke/Neurosurgery

Michelle Curtin

Senior Research Nurse - Stroke/Neurosurgery

Fiona McCurrach

Senior Research Nurse

More EMERGE Trials

Evaluating the role of early CT Coronary Angiography on patients with suspected or confirmed Acute Coronary Syndrome.

Read more

RAPID-CTCA Trial

Evaluating the role of early CT Coronary Angiography

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Read more

ATTEST2 Trial

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Assisting in identifying patients with Humeral shaft fractures in the ED by screening.

Giving patient information sheets to introduce the study, so patient has had adequate time to read and make decision about going into the trial before going to the fracture clinic.

Read more

HU-FIX Trial